Search results for "Progesterone Receptor"

showing 10 items of 56 documents

Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer

1993

Immunohistochemistry of Estrogen Receptor (ER) and Progesterone Receptor (PR) has been performed in 687 cases of human breast cancer. The staining results have been compared by (1) computer-assisted image analysis (QIC Score) and (2) subjective grading of the cryostat sections ("German" IRS). Tumors without or with only weak ER or PR content may be distinguished by both methods from tumors with a high receptor content. The QIC Score values belonging to the intermediate IRS grades are distributed over a wide range, but no negative cases were found in these categories. It is concluded from our results that subjective grading of the slides is a simple, rapid and useful method for the determina…

Oncologymedicine.medical_specialtyPathologybusiness.industrymedicine.drug_classEstrogen receptorCell Biologymedicine.diseasePathology and Forensic MedicineBreast cancerEstrogenInternal medicineProgesterone receptorMedicineImmunohistochemistrybusinessReceptorGrading (tumors)Human breastPathology - Research and Practice
researchProduct

CD1a down-regulation in primary invasive ductal breast carcinoma may predict regional lymph node invasion and patient outcome

2007

Aims: CD1a is a molecule belonging to the highlyconserved group of CD1 proteins. Its expression indendritic cells is related to the presentation of tumour-derived glycolipid antigens to T cells and, consequently,the development of a successful antitumour response.The aim was to investigate the presence of CD1a+ cellsin both primary tumours and lymph nodes (LN) ofa series of 35 invasive ductal carcinomas by bothimmunohistochemistry and reverse transcription-poly-merase chain reaction.Methods and results: CD1a antigen was more expressedin N0 than N1 breast cancer (P < 0.0001) in bothprimary lesions and LN metastases and correlatedpositively and significantly with oestrogen (ER) (P =0.0025) and…

Pathologymedicine.medical_specialtyHistologybusiness.industryCancerGeneral MedicineDendritic cellDuctal carcinomamedicine.diseasePathology and Forensic Medicinemedicine.anatomical_structureBreast cancerProgesterone receptormedicineCarcinomaskin and connective tissue diseasesAntigen-presenting cellbusinessLymph nodeHistopathology
researchProduct

Wertigkeit der Abradathistologie von Endometriumkarzinomen

2002

Objective: We compared immunohistological examination of endometrium biopsy specimen with the results of the immunohistological examination of tumor specimen to analyse the valence of this preoperative examination according to the clinico-pathological findings and overall-survival. Material and Method: Between 1985 and 1995 193 women were treated of an endometrial carcinoma at the University hospital Mainz. In this group we evaluated 41 patients with enough preoperative endometrial biopsy material for a retrospective immunohistochemical analysis and complete follow-up data. The materials from diagnostic curettage were stained and analysed for oestrogen and progesterone receptor status and f…

Pathologymedicine.medical_specialtyHysterectomymedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentObstetrics and GynecologyProgesterone Receptor StatusEndometriummedicine.diseaseCurettagemedicine.anatomical_structurePredictive value of testsBiopsyCarcinomaMedicinebusinessEndometrial biopsyZentralblatt für Gynäkologie
researchProduct

C-myc mRNA Expression in Epithelial Ovarian Carcinomas in Relation to Estrogen Receptor Status, Metastatic Spread, Survival Time, FIGO Stage, and His…

1998

Recently, it has been suggested that c-myc expression might correlate with estrogen receptor (ER) status and metastatic spread in ovarian cancer. In this study, expression of c-myc mRNA in 90 epithelial ovarian carcinomas was determined using the S1 nuclease protection assay. Expression of c-myc mRNA was detectable in 27 of 90 tumors. There was no significant association between c-myc mRNA expression and metastatic spread, survival time, FIGO stage, or histologic grade and type. C-myc mRNA was expressed in 45% of ER-positive tumors but only 24% of ER-negative tumors (p = 0.094; Fisher's exact test). Similarly, 44% of progesterone receptor (PR)-positive and 23% of PR-negative tumors expresse…

Pathologymedicine.medical_specialtymedicine.drug_class10050 Institute of Pharmacology and ToxicologyEstrogen receptor610 Medicine & healthOvaryBiologyPathology and Forensic MedicineMetastasisProto-Oncogene Proteins c-mycProgesterone receptormedicineHumansRNA MessengerRNA NeoplasmSurvival rateEstrogen Receptor StatusOvarian NeoplasmsCarcinomaObstetrics and Gynecology2729 Obstetrics and Gynecologymedicine.diseaseSurvival Rate2734 Pathology and Forensic Medicinemedicine.anatomical_structureReceptors EstrogenEstrogen570 Life sciences; biologyFemaleReceptors ProgesteroneOvarian cancerInternational Journal of Gynecological Pathology
researchProduct

Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast can…

2010

Introduction Accumulating evidence suggests that both levels and activity of the estrogen receptor (ER) and the progesterone receptor (PR) are dramatically influenced by growth-factor receptor (GFR) signaling pathways, and that this crosstalk is a major determinant of both breast cancer progression and response to therapy. The phosphatidylinositol 3-kinase (PI3K) pathway, a key mediator of GFR signaling, is one of the most altered pathways in breast cancer. We thus examined whether deregulated PI3K signaling in luminal ER+ breast tumors is associated with ER level and activity and intrinsic molecular subtype. Methods We defined two independent molecular signatures of the PI3K pathway: a pro…

ProteomeMessengerEstrogen receptorPhosphatidylinositol 3-Kinases0302 clinical medicineReceptorsTumor Cells CulturedInsulin-Like Growth Factor IReceptorCancerOligonucleotide Array Sequence AnalysisMedicine(all)0303 health sciencesCulturedTumorBlottingReverse Transcriptase Polymerase Chain ReactionPrognosis3. Good healthTumor CellsGene Expression Regulation NeoplasticReceptors Estrogen030220 oncology & carcinogenesisFemaleSignal transductionWesternmedicine.drugBiotechnologySignal TransductionResearch Articlemedicine.medical_specialtyBlotting WesternOncology and CarcinogenesisBreast NeoplasmsBiology03 medical and health sciencesInternal medicineProgesterone receptorBreast CancerBiomarkers TumormedicineGeneticsHumansRNA MessengerOncology & CarcinogenesisPI3K/AKT/mTOR pathway030304 developmental biologyCell ProliferationNeoplasticCell growthGene Expression ProfilingEstrogenGene expression profilingEndocrinologyGene Expression RegulationCancer researchRNAProto-Oncogene Proteins c-aktTamoxifenBiomarkersBreast Cancer Research : BCR
researchProduct

Non-genomic effects of progesterone on the signaling function of G protein-coupled receptors

1999

Progesterone at concentrations between 10 microM and 200 microM affected the calcium signaling evoked by ligand stimulation of G protein-coupled receptors expressed in several cell lines. At 160 microM progesterone the signaling of all receptors was completely abolished. The effect of progesterone was fast, reversible and was not prevented by cycloheximide indicating its non-genomic nature. Overall, the action of progesterone was more cell type-specific than receptor-specific. Our results are in contrast to a recent report [Grazzini, E., Guillon, G., Mouillac, B. and Zingg, H.H. (1998) Nature 392, 509-512] in which a direct high-affinity interaction between the oxytocin receptor and progest…

Receptors Neuropeptidemedicine.medical_specialtyReceptors VasopressinTime FactorsBiophysicsStimulationCHO CellsCycloheximideBiologyNon-genomic effectCalcium signalBiochemistryCell Linechemistry.chemical_compoundStructure-Activity RelationshipSpecies SpecificityStructural BiologyInternal medicineCricetinaeProgesterone receptorGeneticsmedicineTumor Cells CulturedAnimalsHumansG protein-coupled receptorCycloheximideReceptorMolecular BiologyProgesteroneG protein-coupled receptorCalcium signalingProtein Synthesis InhibitorsDose-Response Relationship DrugCell BiologyLigand (biochemistry)Oxytocin receptorKineticsEndocrinologychemistryReceptors OxytocinAnisotropyCalciumReceptors CholecystokininSignal TransductionFEBS Letters
researchProduct

High expression of progesterone receptor may be an adverse prognostic factor in oestrogen receptor-negative/progesterone receptor-positive breast can…

2021

Oestrogen receptor (ER)-negative (–) progesterone receptor (PgR)-positive (+) is the least common combination of steroid receptor expression observed in breast cancer. There are many controversies regarding the actual existence of ER–/PgR+ phenotype. In the current study, we aimed to perform comprehensive immunohistochemical re-evaluation of ER–/PgR+ breast cancers from multiple institutions. A total of 135 cases of ER–/PgR+ breast cancer were collected from 11 institutions from the period 2006–2020 and subsequently stained with three clinically validated anti-ER antibody clones: SP1 (Roche), 1D5 (Dako), and EP1 (Dako), and two anti-PgR antibody clones: 636 (Dako), and 1E2 (Roche). Clinicop…

breast cancerReceptors EstrogenOestrogen receptorReceptor ErbB-2immunohistochemistryHumansBreast NeoplasmsFemaleprognosisReceptors Progesteroneprogesterone receptorPathology and Forensic MedicinePathology
researchProduct

Tumor de células de la granulosa extraovárico con mutación FOXL2. Diagnóstico diferencial morfológico e inmunohistoquímico

2020

Extraovarian granulosa cell tumor is a very uncommon tumor and the identification of a recurrent mutation in FOXL2 may be used as another diagnostic tool along with the classical morphological and immunohistochemical findings. Here, we report a new case of extraovarian granulosa cell tumor in a 57 years old female patient presented with a sub-hepatic mass and abdominal pain. Histopathological examination of the excised mass showed features of adult-type granulosa cell tumor with α-inhibin, calretinin, WT1, S100, CD99 and progesterone receptor immunoreactivity. A FOXL2 mutation was detected on molecular biology study. A final diagnosis was an extraovarian adult-type granulosa cell tumor. We …

endocrine systemPathologymedicine.medical_specialtyAbdominal painurogenital systemGranulosa cellCD99BiologyPathology and Forensic Medicine03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisFemale patientProgesterone receptormedicineImmunohistochemistry030211 gastroenterology & hepatologyDifferential diagnosisCalretininmedicine.symptomRevista Española de Patología
researchProduct

Chapter 4 Cholesterol and steroid hormones: modulators of oxytocin receptor function

2002

The function and physiological regulation of the oxytocin-receptor system is strongly steroid-dependent. This is, unexpectedly, only partially reflected by the promoter sequences in the oxytocin receptor and favors the idea that posttranscriptional mechanisms may also play a significant role for the physiological regulation of the oxytocin-receptor system. Our data indicate that cholesterol acts as an allosteric modulator of the oxytocin receptor and stabilizes both membrane-associated and solubilized OT receptors in a high-affinity state for agonists and antagonists. Moreover, high-affinity OT receptors are 2-fold enriched in cholesterol-rich plasma membrane domains in HEK293 fibroblasts s…

medicine.medical_specialtyLiver receptor homolog-1BiologyOxytocin receptorCell biologyEndocrinologyInternal medicineProgesterone receptormedicineEnzyme-linked receptorEstrogen-related receptor gammaFarnesoid X receptor5-HT5A receptorG protein-coupled receptor
researchProduct

Hysteroscopic and ultrasonographic evaluation of ulipristal acetate treatment for symptomatic myomas in premenopausal women: a prospective study

2020

Objective: This study aimed to analyze the effects of a six-month therapy with ulipristal acetate (UPA) on myoma size and endometrial thickness in premenopausal women. Material and methods: Seventy-four women undergoing conservative therapy with UPA were enrolled for this study. All women underwent transvaginal ultrasound evaluation to assess the endometrial thickness, and the number and size of myomas at the beginning and after six months. Hysteroscopy and biopsy were performed after six months, if necessary. Results: After six months of treatment, sonographic examination showed a statistically significant (p &lt;.05) reduction of the size of the largest myoma (56.3 ± 5.1 vs. 31.7 ± 10.1 m…

medicine.medical_specialtyNorpregnadienesUterine fibroidsHysteroscopy03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePregnancyUlipristal acetateSelective progesterone receptor modulatorulipristal acetatemedicineHumansProspective Studiesuterine fibroidsProspective cohort studyGynecologyLeiomyomamedicine.diagnostic_testbusiness.industryMetrorrhagiaMyomaselective progesterone receptor modulatormedicine.diseaseMyomachemistryHysteroscopy030220 oncology & carcinogenesisUterine NeoplasmsFemale030211 gastroenterology & hepatologySurgerymedicine.symptombusinessmetrorrhagia
researchProduct